Hasan, A., Roeh, A., Leucht, S., Langguth, B., Hansbauer, M., Oviedo-Salcedo, T., . . . Falkai, P. (2020). Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial. Contemp Clin Trials Commun.
Styl cytowania ChicagoHasan, Alkomiet, et al. "Add-on Spironolactone As Antagonist of the NRG1-ERBB4 Signaling Pathway for the Treatment of Schizophrenia: Study Design and Methodology of a Multicenter Randomized, Placebo-controlled Trial." Contemp Clin Trials Commun 2020.
Styl cytowania MLAHasan, Alkomiet, et al. "Add-on Spironolactone As Antagonist of the NRG1-ERBB4 Signaling Pathway for the Treatment of Schizophrenia: Study Design and Methodology of a Multicenter Randomized, Placebo-controlled Trial." Contemp Clin Trials Commun 2020.